Calico
Biology research and drug development targeting aging and age-related diseases for patients and clinical partners
Highlights
- New on EvolcAdded 2026-11-16
Recent signals
What changed at Calico in the last 6 months, newest first. Each line links to its public source.
- 15 Oct 2026 Leadership hire · Hiring Associate Director/Director, Biostatistics (South San Francisco) calicolabs.com
- 9 Oct 2026 Leadership hire · Hiring Head of Medical Affairs (South San Francisco) calicolabs.com
About Calico
Calico studies the biology of aging and combines basic research, computational biology, machine learning and drug development to advance potential medicines for age-related diseases.
It conducts translational research across areas including neuroscience, oncology, immunology and aging, and develops clinical- and early-stage programs independently and with industry partners. Its programs include candidates for Vanishing White Matter disease, autosomal dominant polycystic kidney disease and oncology.
Founded in 2013 with support from Google, Calico's own labs became operational in 2015. Its open roles are based in South San Francisco, California.
Product: Aging biology research and discovery and development of potential therapeutics for age-related diseases.
Jobs at Calico
Open roles at Calico in the Americas (7)
United States 7. From Calico's careers page or applicant tracking system; each role links to the employer.
- Principal Scientist, Peptide Chemistry · South San Francisco, United States
- Postdoctoral Fellow, Hahn Lab - Brain Aging · South San Francisco, United States
- Head of Medical Affairs · South San Francisco, United States
- Director, Regulatory CMC · South San Francisco, United States
- Associate Director, Medical Writing · South San Francisco, United States
- Associate Director/Director, Contracts and Alliances · South San Francisco, United States
- Associate Director/Director, Biostatistics · South San Francisco, United States
Leadership
- Arthur D. Levinson · Founder & CEOSource: company website
- John Whiting · Chief Financial OfficerSource: company website
More biotech & pharma companies
cAMPfield Therapeutics
Clinical-stage biopharma developing prifemilast, an oral PDE4B inhibitor, for ulcerative colitis and Crohn's diseaseYoung companyNew on EvolcCapable Labs
AI-driven therapeutics developer building peptide and RNA drugs, starting with sleep disorder programsNew on EvolcCelcuity
Develops targeted cancer therapies for patients with cancers involving the PAM pathwayNew on EvolcCelea Therapeutics
Develops investigational therapies for serious respiratory diseases, including idiopathic pulmonary fibrosisNew on EvolcCellanome
Live-cell imaging and single-cell transcriptomics platform for biology research labs and biopharma companiesNew on EvolcCellarity
AI and multi-omics drug discovery of oral medicines that correct dysfunctional cell states in complex diseasesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Analytics 4High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Privacy & consent
- CookieYesHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
